evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

24 questions · 24 findings · 6 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 8 · 33.3%GRADE not reported 0 · 0%Very low 3 · 12.5%Low 2 · 8.3%Moderate 10 · 41.7%High 1 · 4.2%

Oral ciprofloxacin and inhaled colistin vs inhaled tobramycin (TNS) plus oral ciprofloxacin

Frequency of infective pulmonary exacerbations: number of exacerbations per patient year · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled tobramycin (TNS) vs placebo

Frequency of infective pulmonary exacerbations: number of exacerbations per patient year · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled tobramycin (TNS) (28 days) vs TNS (56 days)

Frequency of infective pulmonary exacerbations: number of exacerbations per patient year · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

It is very uncertain whether inhaled tobramycin (TNS) (28 days) changes frequency of infective pulmonary exacerbations: number of… compared with TNS (56 days) (very low certainty).

1 finding from 1 review

Cycled inhaled tobramycin vs culture‐based TNS

Pulmonary exacerbations · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Cycled inhaled tobramycin (TNS) probably leads to lower frequency of infective pulmonary exacerbations: proportion of… compared with culture‐based TNS (moderate certainty).

1 finding from 1 review

Oral ciprofloxacin and inhaled colistin vs no treatment

Frequency of infective pulmonary exacerbations: number of exacerbations per patient year · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled tobramycin (TNS) plus oral azithromycin vs TNS plus oral placebo

Frequency of infective pulmonary exacerbations: number of participants experiencing an exacerbation · children with cystic fibrosis and a new culture positive for P aeruginosa

Inhaled tobramycin (TNS) plus oral azithromycin showed no clear difference in frequency of infective pulmonary exacerbations: number of… compared with TNS plus oral placebo (moderate certainty).

1 finding from 1 review

Ciprofloxacin vs placebo added to cycled and culture‐based inhaled tobramycin (TNS) therapy

Pulmonary exacerbations · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Ciprofloxacin showed no clear difference in frequency of infective pulmonary exacerbations: proportion of… compared with placebo added to cycled and culture‐based inhaled tobramycin (TNS)… (moderate certainty).

1 finding from 1 review

Summary of findings: aztreonam lysine for inhalation vs tobramycin

Need for antibiotics see pulmonary exacerbations · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: aztreonam lysine for inhalation probably leads to lower pulmonary exacerbations: need for additional antibiotics compared with tobramycin (moderate certainty).

1 finding from 1 review

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

Pulmonary exacerbations · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: colistimethate dry powder for inhalation… showed no clear difference in pulmonary exacerbations: number of pulmonary exacerbations compared with tobramycin (moderate certainty).

1 finding from 1 review

Summary of findings: continuous cycles alternating aztreonam lysine for inhalation with tobramycin for inhalation solution vs continuous cycles alternating placebo with tobramycin

Pulmonary exacerbations: rate of PDEs per participant year · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: continuous cycles alternating aztreonam lysine… showed no clear difference in pulmonary exacerbations: rate of PDEs per participant year compared with continuous cycles alternating placebo with tobramycin (low certainty).

1 finding from 1 review